Nephrogen Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 6

Employees

  • Latest Deal Type
  • Seed

  • Latest Deal Amount
  • $4M

  • Investors
  • 23

Nephrogen General Information

Description

Developer of gene delivery vectors designed to address challenges in creating genomic medicines for kidney and pancreatic diseases. The company integrates artificial intelligence and screening to engineer gene delivery vectors that improve efficiency, reduce immune response, and lower costs of genomic medicine, enabling researchers and clinicians to advance curative genomic therapies and improve patient outcomes.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 1361 Amsterdam Avenue
  • Suite 320
  • New York, NY 10027
  • United States
+1 (814)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 1361 Amsterdam Avenue
  • Suite 320
  • New York, NY 10027
  • United States
+1 (814)

Nephrogen Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Nephrogen Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Seed Round 30-Dec-2025 $4M Completed Generating Revenue
8. Accelerator/Incubator 12-Sep-2025 Completed Generating Revenue
7. Grant 15-Nov-2024 Completed Generating Revenue
6. Accelerator/Incubator 01-Sep-2024 Completed Generating Revenue
5. Seed Round 13-Jul-2023 Completed Generating Revenue
4. Seed Round 12-Oct-2022 Completed Generating Revenue
3. Accelerator/Incubator 01-Sep-2022 Completed Generating Revenue
2. Accelerator/Incubator 24-Jun-2022 Completed Generating Revenue
1. University Spin-Out 01-Sep-2022 Completed Startup
To view Nephrogen’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Nephrogen Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of gene delivery vectors designed to address challenges in creating genomic medicines for kidney and pancreati
Drug Discovery
New York, NY
6 As of 2026

New York, NY
 

New York, NY
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Nephrogen Competitors (3)

One of Nephrogen’s 3 competitors is Helex, a Venture Capital-Backed company based in New York, NY.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Helex Venture Capital-Backed New York, NY
Nionyx Venture Capital-Backed New York, NY
Estuary Biotherapeutics Venture Capital-Backed Menlo Park, CA
You’re viewing 3 of 3 competitors. Get the full list »

Nephrogen Patents

Nephrogen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4728074-A2 Systems, methods, and compositions for de-repressing pkd1 Pending 13-Jun-2023
WO-2024259175-A2 Systems, methods, and compositions for de-repressing pkd1 Inactive 13-Jun-2023
WO-2024259175-A3 Systems, methods, and compositions for de-repressing pkd1 Inactive 13-Jun-2023
US-10908156-B2 Portable instrument for in vitro detection and quantification of biomarkers Active 21-Mar-2014
US-20170097344-A1 Portable instrument for in vitro detection and quantification of biomarkers Active 21-Mar-2014 G01N33/54386
To view Nephrogen’s complete patent history, request access »

Nephrogen Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Nephrogen Investors (23)

Investor Name Investor Type Holding Investor Since Participating Rounds
Angel (individual)
Angel (individual)
Gaingels Venture Capital Minority
Mercury Software (Germany) Venture Capital Minority
Milkbox Partners Venture Capital Minority
You’re viewing 5 of 23 investors. Get the full list »

Nephrogen FAQs

  • When was Nephrogen founded?

    Nephrogen was founded in 2015.

  • Where is Nephrogen headquartered?

    Nephrogen is headquartered in New York, NY.

  • What is the size of Nephrogen?

    Nephrogen has 6 total employees.

  • What industry is Nephrogen in?

    Nephrogen’s primary industry is Drug Discovery.

  • Is Nephrogen a private or public company?

    Nephrogen is a Private company.

  • What is Nephrogen’s current revenue?

    The current revenue for Nephrogen is .

  • How much funding has Nephrogen raised over time?

    Nephrogen has raised $4.97M.

  • Who are Nephrogen’s investors?

    , , Gaingels, Mercury Software (Germany), and Milkbox Partners are 5 of 23 investors who have invested in Nephrogen.

  • Who are Nephrogen’s competitors?

    Helex, Nionyx, and Estuary Biotherapeutics are competitors of Nephrogen.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process